Huishan Medical Secures New Round of Funding Led by Shoujian Investment to Advance Cell Therapy for Immune Diseases

Jan 07, 2025 17:06 CST Updated 17:06

Investment Circle (ID: pedaily2012) January 7th, by reporter, Guangzhou Huishan Medical Technology Co., Ltd. ("Huishan Medical" for short) obtainedA new round of financing.The lead investor in this round of financingSub-funds under Jian Tou, and the funds will be mainly used for the construction of the company's GMP workshop and IND application.

Guangzhou Huishan Medical Technology Co., Ltd. is an innovative enterprise focusing on the field of cellular medicine for immune diseases. It is committed to the research and application of cell regenerative medicine technology. With immune diseases that seriously endanger people's health as the entry point, the company aims to improve the specialized disease prevention system and precision diagnosis and treatment as its product development direction. It has laid out its efforts in areas such as immune function testing, immune cell storage and drug development, and biomedical engineering cell medicine research and development.Aimed at building an immune cell regenerative medicine industry chain to provide new solutions for improving the precise diagnosis and treatment of immune diseases.

[This article is published based on public information. If you have any objections, please contact (editor@zero2ipo.com.cn) for Investment Realm to address the matter.]